Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
ROOT, Switzerland–(BUSINESS WIRE)–$NVCR–Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including... Read more.
Northern Trust Named Best Private Bank for Family Offices and Succession Planning
CHICAGO–(BUSINESS WIRE)–#wealthmanagement–Northern Trust, a leading provider of wealth management services, has taken top honors in two categories... Read more.
NanoSyrinx appoints Anthony Johnson as Non-Executive Director
Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy COVENTRY, United Kingdom–(BUSINESS WIRE)–NanoSyrinx,... Read more.
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Opinion granted based on positive overall survival results from the Phase 3 KEYNOTE‑966 trial RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE:... Read more.
National Vision Holdings, Inc. Announces Repurchase of $100 Million of Convertible Notes
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision”) today announced that it has entered into agreements... Read more.
Bowman Acquires Reno-Based Engineering Firm CFA, Inc.
RESTON, Va.–(BUSINESS WIRE)–Bowman Consulting Group Ltd. (the “Company” or “Bowman”) (NASDAQ: BWMN), a national engineering services firm delivering... Read more.
CI Financial Announces Commencement of Substantial Issuer Bid
TORONTO–(BUSINESS WIRE)–$CIX #CIFinancial–CI Financial Corp. (TSX: CIX) (“CI Financial” or the “Corporation”) announced today it has commenced... Read more.
FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data at the Society for Neuro-Oncology 2023 Annual Meeting
PHILADELPHIA–(BUSINESS WIRE)–FORE Biotherapeutics today announced an oral presentation highlighting updated Phase 1/2a clinical data for plixorafenib... Read more.
Soho House & Co Inc. Announces Third Quarter 2023 Results
LONDON–(BUSINESS WIRE)–$SHCO–Soho House & Co Inc. (NYSE: SHCO) (“SHCO,” “Company,” “we” or “our”), a global membership platform... Read more.
JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA
HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that the first... Read more.